In Segment C, individuals will acquire ABBV-744 and oral navitoclax. In Phase D, participants will receive ABBV-744 and ruxolitinib. Contributors will acquire treatment until eventually disease progression or even the individuals are not able to tolerate the study drugs. 88 These preclinical studies supply paradigms for long term clinical trials https://jeanc322ozj5.blogolenta.com/profile